12:00 AM
Oct 21, 2013
 |  BC Week In Review  |  Company News  |  Other News

Bayer, Natco cancer, generics news

Bayer said it is pursuing in the Mumbai High Court a case against Natco's compulsory license in India to manufacture and market a generic version of Bayer's Nexavar sorafenib for kidney and liver cancer. The court is a level below India's Supreme...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >